CN102811722A - 用石房蛤毒素衍生物对触觉丧失进行的治疗 - Google Patents

用石房蛤毒素衍生物对触觉丧失进行的治疗 Download PDF

Info

Publication number
CN102811722A
CN102811722A CN2011800149701A CN201180014970A CN102811722A CN 102811722 A CN102811722 A CN 102811722A CN 2011800149701 A CN2011800149701 A CN 2011800149701A CN 201180014970 A CN201180014970 A CN 201180014970A CN 102811722 A CN102811722 A CN 102811722A
Authority
CN
China
Prior art keywords
scb
pharmaceutical composition
derivatives
administration
superficial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800149701A
Other languages
English (en)
Chinese (zh)
Inventor
马克斯·拉特曼
让·雅克·皮洛格特
康斯坦扎·西格拉
巴勃罗·巴伦苏埃拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytotox Ltd
Original Assignee
Phytotox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytotox Ltd filed Critical Phytotox Ltd
Publication of CN102811722A publication Critical patent/CN102811722A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800149701A 2010-02-10 2011-02-10 用石房蛤毒素衍生物对触觉丧失进行的治疗 Pending CN102811722A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153234.9 2010-02-10
EP10153234 2010-02-10
US31290310P 2010-03-11 2010-03-11
US61/312,903 2010-03-11
PCT/EP2011/051992 WO2011098539A1 (en) 2010-02-10 2011-02-10 Treatment of loss of sense of touch with saxitoxin derivatives

Publications (1)

Publication Number Publication Date
CN102811722A true CN102811722A (zh) 2012-12-05

Family

ID=43828310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800149701A Pending CN102811722A (zh) 2010-02-10 2011-02-10 用石房蛤毒素衍生物对触觉丧失进行的治疗

Country Status (6)

Country Link
US (2) US9107925B2 (enExample)
EP (1) EP2533785B1 (enExample)
JP (2) JP6112867B2 (enExample)
CN (1) CN102811722A (enExample)
ES (1) ES2484315T3 (enExample)
WO (1) WO2011098539A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831945A (zh) * 2017-03-29 2020-02-21 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9107925B2 (en) * 2010-02-10 2015-08-18 Phytotox Limited Sodium channel blocker for treatment of loss of superficial sensitivity
EP2638908A1 (en) * 2012-03-16 2013-09-18 Phytotox SpA Paralytic Shellfish Poison
PL2968225T3 (pl) * 2013-03-15 2019-08-30 The Children's Medical Center Corporation Preparaty skojarzone neosaksytoksyny do przedłużonego znieczulenia miejscowego
CA2944549A1 (en) * 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
CA3000708A1 (en) * 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process
JP2020515611A (ja) * 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
US12162886B2 (en) 2018-10-03 2024-12-10 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CA3188924A1 (en) * 2020-08-14 2022-02-17 Hassan Pajouhesh Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
WO2022112887A1 (en) * 2020-11-25 2022-06-02 Algenis Method of treating acute nociceptive pain in mammals

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585642A (zh) * 2001-11-15 2005-02-23 微观藻类公司 包含3,4－丙炔基全氢化嘌呤的药物组合物及其在阻滞神经元传递方面的应用
WO2005110418A2 (en) * 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
CN1997373A (zh) * 2004-05-07 2007-07-11 菲特托克斯有限公司 藻毒素及其用途
CN101563079A (zh) * 2006-03-27 2009-10-21 威克斯药业有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
KR20070083650A (ko) * 2004-09-21 2007-08-24 라보라토리오스 델 드라. 에스테브.에스.에이. 중추 신경적으로 유발된 신경병증성 통증을 치료하기 위한테트로도톡신 및 그것의 유도체
EP1799220A1 (en) 2004-09-22 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain
US9107925B2 (en) * 2010-02-10 2015-08-18 Phytotox Limited Sodium channel blocker for treatment of loss of superficial sensitivity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585642A (zh) * 2001-11-15 2005-02-23 微观藻类公司 包含3,4－丙炔基全氢化嘌呤的药物组合物及其在阻滞神经元传递方面的应用
WO2005110418A2 (en) * 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
CN1997373A (zh) * 2004-05-07 2007-07-11 菲特托克斯有限公司 藻毒素及其用途
CN101563079A (zh) * 2006-03-27 2009-10-21 威克斯药业有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831945A (zh) * 2017-03-29 2020-02-21 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
CN110831945B (zh) * 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物

Also Published As

Publication number Publication date
US20160000793A1 (en) 2016-01-07
JP2013519653A (ja) 2013-05-30
ES2484315T3 (es) 2014-08-11
EP2533785A1 (en) 2012-12-19
US9107925B2 (en) 2015-08-18
EP2533785B1 (en) 2014-04-23
US20130039976A1 (en) 2013-02-14
JP6112867B2 (ja) 2017-04-12
WO2011098539A1 (en) 2011-08-18
JP2017081920A (ja) 2017-05-18

Similar Documents

Publication Publication Date Title
CN102811722A (zh) 用石房蛤毒素衍生物对触觉丧失进行的治疗
CN105142625B (zh) 用于长效局部麻醉的新蛤蚌毒素组合配制品
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
KR20180012745A (ko) 염증 및 면역 질환을 치료하는 방법 및 조성물
JP2004507496A5 (enExample)
KR20060121238A (ko) 축적된 지방의 의약적 지방 분해
KR20180100309A (ko) 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법
RU2633637C2 (ru) Паралитический яд моллюсков
JP2024531685A (ja) 神経障害の処置
US20060205699A1 (en) Topical treatment for psoriasis
Cantisani et al. New patents on topical anesthetics
US20140113883A1 (en) Therapeutic micro nutrient composition for lipolysis and sclerosis
RU2200557C1 (ru) Способ лечения гипертрофических и келоидных рубцов
JPH061721A (ja) 疼痛処置剤、及び疼痛軽減作用増強剤
HK1179530B (en) Treatment of loss of sense of touch with saxitoxin derivatives
HK1179530A (en) Treatment of loss of sense of touch with saxitoxin derivatives
US20090221528A1 (en) Therapeutic micro nutrient composition for lipolysis and sclerosis
JP2001163783A (ja) 皮膚疾患治療用外用剤
WO2024121065A1 (en) Dyclonine for use in the topical treatment of hand-foot syndrome
RU2147440C1 (ru) Обезболивающее и противозудное средство
TW202515529A (zh) 用於治療異位性皮膚炎之雜環衍生物
CN116348091A (zh) 用于长期麻醉的肠胃外剂型的药物组合
HK1205934B (en) Paralytic shellfish poison for the treatment of itch
JP2001163782A (ja) 皮膚疾患治療用外用剤
HK1174049A (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121205